Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Trading Update

25 Jan 2021 07:00

RNS Number : 6804M
Sopheon PLC
25 January 2021
 

Embargoed release: 07:00hrs Monday 25 January 2021

 

 

 

SOPHEON PLC

("Sopheon", the "Company" or the "Group")

 

TRADING UPDATE

 

Sopheon, the international provider of software and services for Enterprise Innovation Management solutions, provides the following trading update for the year ended 31 December 2020.

 

As in prior years, the final quarter was the strongest of the year for the Group, and in fact stronger than 2019, despite the resurgence of Covid concerns globally. We are pleased to report ongoing commercial traction and material progress in two strategic areas of focus: migration to a Software as a Service ("SaaS") recurring revenue model - giving both enhanced revenue visibility to future periods and improved quality of earnings - and landing large enterprise class contracts with major companies.

 

Total contract value ("TCV") of signed SaaS business grew 274% year on year, due to rapid adoption by our sales teams of the SaaS model for new customers, as well as converting some existing perpetual customers. Annual Recurring Revenue ("ARR") gross retention for the year remained respectable, at 91.5% (2019: 94.2%) but this represented greater than normal attrition, which is unsurprising given the challenging market conditions for some customers last year. Overall, the TCV of all sales bookings increased by 23% year on year, but the shift of emphasis from perpetual to multi-year SaaS means that most of this revenue will be recognized over time, rather than in the year of sale. New wins included global brands such as DuPont and LG, alongside previously announced Mondelēz and Orion. Six of our new customers had initial deal value at $1m or more, compared to just one in 2019, underlining material traction with enterprise sales even in these difficult times.

 

We expect that revenue for the year ended 31 December 2020 will be approximately $30m, in line with our 2019 performance. ARR is expected to rise to $18m (2019: $15.9m). This, coupled with a substantial order book of services, means that revenue visibility1 for 2021 is already at $22m (2019: $18.9m) giving cause for optimism regarding the year ahead.

 

Adjusted EBITDA is expected to be in the region of $5.6m (2019: $6.4m). Net cash on 31 December 2020 was $21.6m (2019: $19.4m), demonstrating the cash generative nature of the business as well as the robust balance sheet. As noted previously, billing seasonality means that this number should rise in the early part of 2021. In addition, costs reflect initial investments in a native cloud platform to enable new SaaS products, that will take us into new market segments. This was in parallel with further investments in our enterprise Accolade platform. These initiatives will continue in 2021.

 

Financial expectations noted above are preliminary, and subject to year-end financial close and audit review processes. In line with our normal reporting schedule, Sopheon plans to issue its results for the year ended 31 December 2020 on 24 March 2021.

 

Sopheon's Chairman, Barry Mence said: "I'm very proud that Sopheon has been able to match prior year revenue and grow total sales bookings in such a difficult global climate. We've done this while simultaneously embarking on a migration of our business from up-front perpetual license sales to a SaaS subscription model - leading to a solid increase in recurring revenues, and providing greater visibility to future years. We believe we have a substantial opportunity ahead of us, and our strong balance sheet gives us the confidence to maintain ambitious investment plans through the pandemic and beyond."

 

 

For further information contact:

Barry Mence (Chairman)Arif Karimjee (CFO)

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes/Giles Rolls (Corporate Finance)Alice Lane / Sunila de Silva (ECM)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

1 Revenue visibility is defined on page 7 of Sopheon's 2019 annual report which is available from the investor section of www.sopheon.com.

 

The information communicated in this announcement is inside information

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDZLFLFFLBBBQ
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.